Further investigation is necessary to determine if certain combinations of PD-L1 tumor cell expression and TMB status (i.e. PD-L1TPS≥50% and TMB>10mutations/Mb) are associated with better response to immunotherapy when compared to a single biomarker test and its correlation with potential resistant immunotherapy biomarkers such as STK11, KEAP1, and EGFR. This evidence concerns the gene EGFR and neoplasm.